Adagio Medical Holdings, Inc. (ADGM)

AI-Powered SEC Filing Analysis

Current Report Filed: 2026-04-27

Key Insights

Adagio Medical announced positive pivotal trial results for its vCLAS® Ventricular Ablation System, a potentially significant milestone that could support regulatory approval and future commercialization of this cardiac ablation device.
The company is an emerging growth company trading on Nasdaq under ticker ADGM, indicating it is a smaller public company in a growth phase with regulatory pathways ahead.
The filing was signed by CFO and Chief Business Officer Deborah Kaster on April 27, 2026, suggesting the company actively manages investor communications and corporate governance.

Current Report Filed: 2026-04-08

Key Insights

Adagio Medical received IDE approval from the FDA to investigate its next-generation vCLAS™ Ventricular Ablation System, indicating progress in the company's product development pipeline.
The filing does not contain any financial information or updates, suggesting this is a regulatory/operational update rather than a performance-related filing.
As an emerging growth company, Adagio Medical may have flexibility in reporting requirements and adoption of new accounting standards, which could impact future financial disclosures.

Current Report Filed: 2026-03-27

Key Insights

Adagio Medical Holdings, Inc. announced its Q4 and fiscal year 2025 financial results, providing investors with an update on the company's performance and operations.
The company did not report any material agreements, leadership changes, or other significant events that could impact its business operations or financial condition.
As an emerging growth company, Adagio has elected not to use the extended transition period for complying with new or revised financial accounting standards, which could indicate a focus on transparency and adherence to reporting standards.

Annual Report Filed: 2026-03-27

Key Insights

Adagio Medical Holdings, Inc. (ADGM) reported significant increases in intangible asset impairment charges and convertible securities/warrants over the past 3 years, indicating potential financial and operational challenges.
The company has relied heavily on related party transactions with Fjord Ventures for shared services and office/manufacturing space, raising concerns about conflicts of interest and financial dependence.
Adagio Medical has implemented several new equity incentive plans over the past few years, suggesting potential dilution for common shareholders.

Insider Trading Filed: 2026-03-09

Key Insights

The CEO, Todd Usen, has been granted 800,000 stock options as part of the company's 2024 Equity Incentive Plan. This suggests the company is incentivizing its leadership to drive long-term growth and value creation.
The options will vest over a four-year period, aligning the CEO's interests with those of shareholders. This type of compensation structure is common for public company executives.
The exercise price of the options is $0.977, which appears to be at or near the current market price, indicating the company is not issuing discounted options to insiders.

Insider Trading Filed: 2026-03-09

Key Insights

Deborah Kaster, the Chief Financial Officer of Adagio Medical Holdings, Inc., has acquired 490,500 employee stock options with an exercise price of $0.977 per share.
The options will vest over a four-year period, with 25% vesting on October 20, 2026 and the remaining shares vesting in equal monthly installments over the next 36 months.
This equity grant suggests that Kaster is being incentivized to continue in her role and drive the company's long-term success.

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.